Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Want to see BLRX full AI Analyst Report?
Top Page
Bioline RX Ltd Sponsored ADR
(NASDAQ:BLRX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.00
▲(22.45% Upside)
Action:Reiterated
Date:06/08/26
The score is held back primarily by weak financial performance (ongoing losses and cash burn despite improving revenue and strong gross margin). Technicals are moderately supportive with price above key moving averages and positive MACD. Earnings-call updates add some offset via clear clinical milestones and improving royalties, but the limited cash runway and reduced non-operating income temper confidence. Valuation support is limited due to negative earnings and no dividend yield.
Positive Factors
Commercial traction for APHEXDA and rising royalties
Partner-driven APHEXDA royalties create a recurring, asset-backed revenue stream that rose materially in Q1 2026 (APHEXDA sales $2.5M; $0.5M royalties). Combined with a strong reported gross margin (~74.7%), this supports unit economics, funds R&D and reduces the need for a direct sales infrastructure over the medium term.
Negative Factors
Limited cash runway into H1 2027
With ~$17.4M of cash covering operations into H1 2027, short runway constrains ability to complete GLIX1 dose escalation, support PDAC enrollment and sustain parallel programs. This raises near-term financing or partnering probability, which can delay timelines and dilute upside for existing shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction for APHEXDA and rising royalties
Partner-driven APHEXDA royalties create a recurring, asset-backed revenue stream that rose materially in Q1 2026 (APHEXDA sales $2.5M; $0.5M royalties). Combined with a strong reported gross margin (~74.7%), this supports unit economics, funds R&D and reduces the need for a direct sales infrastructure over the medium term.
Read all positive factors
Bioline RX Ltd Sponsored ADR (BLRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.46M
Dividend YieldN/A
Average Volume (3M)23.61K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth-93.71%
EPS Growth23.89%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.12
Shares Outstanding4,368,295
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue15.29
Enterprise Value/Gross Profit20.47
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$12.00Price Target Upside389.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$1.72M
Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model
Company Description
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successful...
How the Company Makes Money
BioLineRx generates revenue primarily from (1) product-based income tied to APHEXDA (motixafortide) via its commercial arrangement and (2) collaboration-related income such as upfront payments, milestones, and royalties from partners (when applica...
Bioline RX Ltd Sponsored ADR Earnings Call Summary
Earnings Call Date:May 27, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Neutral
The call conveyed meaningful clinical progress—most notably initiation and first dosing in the GLIX1 first-in-human study, supportive preclinical data including activity in temozolomide-resistant models, ASCO exposure, and accelerating APHEXDA sales via partner Ayrmid. Offsetting these positives were materially weaker financial results versus prior year (swing to a $2.6M net loss, a ~93% drop in nonoperating income), higher R&D spend tied to GLIX1, and a modest cash runway into H1 2027. Operational transparency was limited on some site activations, dosing and commercial execution by the partner. Overall, scientific and programmatic momentum is strong but financial and disclosure constraints introduce caution.Positive Updates
GLIX1 First-in-Human Trial Initiation and Dosing
Phase I/IIa trial for GLIX1 in glioblastoma (GBM) initiated; first patient dosed at NYU Langone. Trial Phase I expects up to 30 recurrent GBM/high-grade glioma patients to determine MTD/RDose based on safety, PK/PD and preliminary efficacy. Periodic updates expected in H2 2026, full dose-escalation results anticipated in 2027.
Negative Updates
Swing to Net Loss
Net loss of $2.6M in Q1 2026 versus net income of $5.1M in Q1 2025 — an adverse swing of $7.7M year-over-year, reflecting weaker overall profitability this quarter.
Read all updates
Q1-2026 Updates
Positive
Negative
GLIX1 First-in-Human Trial Initiation and Dosing
Phase I/IIa trial for GLIX1 in glioblastoma (GBM) initiated; first patient dosed at NYU Langone. Trial Phase I expects up to 30 recurrent GBM/high-grade glioma patients to determine MTD/RDose based on safety, PK/PD and preliminary efficacy. Periodic updates expected in H2 2026, full dose-escalation results anticipated in 2027.
Read all positive updates
Company Guidance
The company provided clear near‑term guidance and milestones: GLIX1 Phase I/IIa was initiated in March with the first patient dosed, three academic centers participating, a Phase I dose‑escalation of up to ~30 recurrent/high‑grade GBM patients, periodic updates expected in H2 2026 and full dose‑escalation results in 2027, and a planned Phase IIa expansion (newly diagnosed GBM and select cancers, including combinations with PARP inhibitors); preclinical data showed dose‑dependent tumor inhibition in 2 orthotopic CDx models and activity in a temozolomide‑resistant PDX, with tox studies up to 2,000 mg/kg in rats indicating a large safety margin. For PDAC, the CheMo4METPANC randomized Phase IIb (motixafortide + cemiplimab + gem/nab‑paclitaxel) is enrolling with a prespecified interim futility analysis at 40% of PFS events anticipated later this year. Financial guidance/metrics: Q1 2026 revenues $0.5M (vs $0.3M), R&D $2.5M (vs $1.6M), G&A $0.9M (vs $1.0M), net non‑operating income $0.5M (vs $7.6M), net loss $2.6M (vs net income $5.1M), cash and equivalents $17.4M (funding planned operations into H1 2027); APHEXDA sales were $2.5M in Q1 2026 (vs $1.4M in Q1 2025) generating $0.5M of royalties. Market context metrics cited include median GBM survival ~12–18 months, 2030 incidence ~18,500 U.S. and ~13,500 EU4+1 patients, and a U.S./Europe TAM >$3.7B.Bioline RX Ltd Sponsored ADR Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.40M | 1.19M | 28.94M | 4.80M | 0.00 | 0.00 |
| Gross Profit | 1.05M | 430.39K | 19.68M | 1.11M | 0.00 | 0.00 |
| EBITDA | -8.20M | -224.77K | 3.92M | -57.09M | -22.14M | -25.37M |
| Net Income | -8.89M | -1.18M | -9.22M | -60.61M | -24.95M | -27.05M |
Balance Sheet | ||||||
| Total Assets | 38.80M | 40.90M | 38.91M | 63.92M | 76.38M | 81.39M |
| Cash, Cash Equivalents and Short-Term Investments | 17.35M | 20.88M | 19.56M | 42.99M | 51.08M | 57.13M |
| Total Debt | 9.07M | 10.15M | 15.04M | 11.59M | 12.32M | 4.65M |
| Total Liabilities | 17.96M | 17.56M | 25.45M | 50.70M | 25.54M | 13.30M |
| Stockholders Equity | 16.67M | 18.20M | 13.46M | 13.22M | 50.84M | 68.09M |
Cash Flow | ||||||
| Free Cash Flow | -7.82M | -8.16M | -43.93M | -22.91M | -26.56M | -23.67M |
| Operating Cash Flow | -7.79M | -8.14M | -43.87M | -22.61M | -26.24M | -23.57M |
| Investing Cash Flow | 2.33M | -8.61M | 29.37M | 1.44M | 4.01M | -38.22M |
| Financing Cash Flow | -1.75M | 8.95M | 20.66M | 15.06M | 20.44M | 57.75M |
Bioline RX Ltd Sponsored ADR Technical Analysis
Positive
2.45
Price Trends
2.85
Positive
2.81
Positive
3.14
Positive
Market Momentum
0.13
Positive
56.35
Neutral
51.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Positive. The current price of 2.45 is below the 20-day moving average (MA) of 3.22, below the 50-day MA of 2.85, and below the 200-day MA of 3.14, indicating a bullish trend. The MACD of 0.13 indicates Positive momentum. The RSI at 56.35 is Neutral, neither overbought nor oversold. The STOCH value of 51.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLRX.
Bioline RX Ltd Sponsored ADR Risk Analysis
Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline RX Ltd Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $12.82M | -1.77 | -89.92% | ― | ― | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.46M | -1.63 | -22.03% | ― | -93.71% | 23.89% | |
49 Neutral | $8.77M | -14.31 | -27.54% | ― | ― | -138.25% | |
44 Neutral | $14.41M | -0.36 | ― | ― | ― | 80.65% | |
44 Neutral | $15.72M | -0.26 | -67.42% | ― | ― | 55.15% | |
42 Neutral | $17.96M | -0.49 | -135.04% | ― | ― | 42.29% |
* Healthcare Sector Average
BLRX
Bioline RX Ltd Sponsored ADR
3.37
-1.32
-28.14%
SYBX
Synlogic
0.74
-0.51
-40.66%
MBRX
Moleculin Biotech
2.64
-13.41
-83.55%
CTXR
Citius Pharmaceuticals
0.54
-0.33
-38.22%
CMMB
Chemomab Therapeutics
1.65
-3.15
-65.63%
PASG
Passage Bio
5.81
-2.01
-25.70%
Bioline RX Ltd Sponsored ADR Corporate Events
BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend
May 27, 2026
BioLineRx Ltd. reported unaudited first-quarter 2026 results on May 27, 2026, alongside a corporate update that underscored rapid progress in its GLIX1 oncology program. The company initiated a Phase 1/2a trial for GLIX1 in March, dosed the first ...
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls
May 22, 2026
On May 22, 2026, BioLineRx and Hemispherian announced that two abstracts on their lead candidate GLIX1 will be featured at the ASCO 2026 Annual Meeting in Chicago, underscoring rising scientific interest in this first-in-class TET2-activating smal...
BioLineRx and Hemispherian Report Strong Preclinical GLIX1 Data in Temozolomide-Resistant Glioblastoma
May 19, 2026
On May 19, 2026, BioLineRx and Hemispherian reported new preclinical data for GLIX1, an orally administered, brain-penetrating TET2 pathway activator, showing robust anti-tumor activity in multiple glioblastoma models. The drug produced significan...
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial
Apr 28, 2026
BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing GLIX1 as its lead asset, targeting DNA damage response in glioblastoma and other solid tumors, alongside its approved stem cell mob...
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma
Mar 26, 2026
BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing a pipeline led by GLIX1, a first-in-class DNA damage response modulator for glioblastoma and other solid tumors, alongside its appr...
BioLineRx Sets March Start for GLIX1 Brain Cancer Trial as 2025 Results Show Leaner R&D-Focused Model
Mar 23, 2026
On March 23, 2026, BioLineRx reported audited 2025 results and said it remains on track to launch a Phase 1/2a first-in-human trial of GLIX1 in glioblastoma by the end of March, with three leading U.S. cancer centers participating. The study will ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.